Clinical Trial Search

Primary: Latent Dirichlet Allocation (LDA) Topics - Topics / Themes Discussed Between Patients With and Without Heart Disease — 0.85; 0.87; 0.55; 0.67 proportion probability AUC…

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index

Primary: Change From Baseline in % Flow Mediated Dilatation (FMD) — 0.09; 0.32 %FMD

Primary: Hamilton Depression Rating Scale — -7.5; -6.1; -4.5 Raw changes in Ham-D scores

Primary: Absolute Change From Baseline in HDL-C — 12.76; 0.50 mg/dL

Primary: Percent Change From Baseline in Mean Wall Thickness — 4.245; 6.679 Percent Change

Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement

Primary: Participation in Cardiac Rehabilitation — 231; 252 Participants — p=0.80

Primary: Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) — 14.1 Percent Change

Primary: Compare Change in Platelet Aggregation as Measured by Adenosine Diphosphate (ADP) Between PGJ and Placebo — 1.59; -12.3 percent

Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale

Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration — 48.08; 66.79 MIF Concentration,ug/L

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 17; 10; 11; 12 Participants

Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001

Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale

Primary: Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level — 678 Participants

Primary: Change From Baseline in C-Reactive Protein Level at 6 Months — 6.30; 4.94 mg/L

Primary: Percent Change From Baseline in HDL-C — 33.76; 3.69 Percentage Change of HDL-C

Primary: Change in Pulse Wave Velocity (PWV) — -0.25; -0.16 m/s

Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants

Primary: High-sensitivity C-reactive Protein — 1.0; 1.0 mg/dl — p=0.22

Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement

Primary: Feasibility - Number of Enrolled Participants — 38 Participants

Primary: Change of Daytime Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Pre-treatment and Post-treatment — -8; -3; -4; -3 mm Hg — p=<0.05

Primary: 6-minute Walking Distance (Meters) — 506.1; 489.8 meters — p=0.04

Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change

Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…